Skip to main content
All lobbying filings

SAREPTA THERAPEUTICS, INC.

SAREPTA THERAPEUTICS, INC. filed a Q2 report for SAREPTA THERAPEUTICS, INC. on July 20, 2026.

Lobbying for SAREPTA THERAPEUTICS, INC.

All filings by SAREPTA THERAPEUTICS, INC. · Everything SAREPTA THERAPEUTICS, INC. has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 20, 2026
Expenses
$220,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
California

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 4
Budget/Appropriations

H.R. 9260 - LHHS Appropriations

Health Issues

H.R. 1509 - Accelerating Kids Access to Care Act Patient Access Act Issues related to patient access to treatment

Science/Technology

National Security Commission on emerging biotechnology policy proposals

Trade (domestic/foreign)

Issues related to supply chain Issues related to Section 232

 Bills named in this filing 2
  • H.R. 9260
    Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
  • H.R. 1509
    Accelerating Kids’ Access to Care Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem